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Abstract 
Background: Adenosine-free coronary pressure wire metrics have been proposed to test the functional significance 
of coronary artery lesions, but it is unexplored whether their diagnostic performance might be altered in patients with 
diabetes.
Methods: We performed a post-hoc analysis of the CONTRAST study, which prospectively enrolled an international 
cohort of patients undergoing routine fractional flow reserve (FFR) assessment for standard indications. Paired, 
repeated measurements of all physiology metrics (Pd/Pa, iFR, contrast-based FFR, and FFR) were made. A central core 
laboratory analyzed blinded pressure tracings in a standardized fashion.
Results: Of 763 subjects enrolled at 12 international centers, 219 (29%) had diabetes. The two groups were well-
balanced for age, clinical presentation (stable or unstable), coronary vessel studied, volume and type of intracoronary 
contrast, and volume of intracoronary adenosine. A binary threshold of cFFR ≤ 0.83 produced an accuracy superior 
to both Pd/Pa and iFR when compared with FFR ≤ 0.80 in the absence of significant interaction with diabetes status; 
indeed, accuracy in subgroups of patients with or without diabetes was similar for cFFR (86.7 vs 85.4% respectively; 
p = 0.76), iFR (84.2 vs 80.0%, p = 0.29) and Pd/Pa (81.3 vs 78.9%, p = 0.55). There was no significant heterogene-
ity between patients with or without diabetes in terms of sensitivity and specificity of all metrics. The area under 
the receiver operating characteristic (ROC) curve was largest for cFFR compared with Pd/Pa and iFR which were 
equivalent (cFFR 0.961 and 0.928; Pd/Pa 0.916 and 0.870; iFR 0.911 and 0.861 in diabetic and non-diabetic patients 
respectively).
Conclusions: cFFR provides superior diagnostic performance compared with Pd/Pa or iFR for predicting FFR irre-
spective of diabetes (clinicaltrials.gov identifier NCT02184117).
Keywords: Diabetes, Coronary lesion, Fractional flow reserve, Hyperemia, Contrast medium, Adenosine, Resting 
metrics, Instantaneous wave-free ratio
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Background
Due to its multi-test validation and cost-effective 
improvement in clinical outcomes demonstrated by 
multiple randomized trials as well as observational data, 
physiological assessment of coronary stenoses by frac-
tional flow reserve (FFR) has emerged as the gold stand-
ard for making revascularization decisions on stable 
lesions [1–5]. Importantly, FFR requires hyperemia, but 
that does add a small cost and risk [1, 6, 7]. Therefore, the 
CONTRAST (Can cONTrast Injection Better Approxi-
mate FFR compAred to Pure reSTing Physiology?) study 
recently investigated whether contrast medium could 
provide an easy alternative and inexpensive tool for 
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assessing FFR (namely contrast FFR, cFFR). It demon-
strated that cFFR was superior to resting measurements 
(rest distal pressure [Pd]/aortic pressure [Pa], and the 
instantaneous wave-free ratio [iFR]) in terms of diagnos-
tic performance to predict FFR [8].
Diabetes mellitus increases cardiovascular risk, which 
has been attributed mainly to its detrimental effects on 
vascular function [9–13]. Before contributing to the 
development of structural vascular changes or significant 
coronary artery disease (CAD), diabetes impairs endothe-
lial function leading to microvascular dysfunction [12–
18]. Even in diabetic patients without additional cardiac 
risk factors, endothelial dysfunction has been demon-
strated and explained by associated autonomic dysfunc-
tion, chronic hyperglycemia, and insulin resistance.
Diabetes does not seem to significantly impact FFR 
accuracy or its interpretation [4, 19–22], although it 
can produce coexisting epicardial lesions (quantified by 
FFR) and microvascular dysfunction (often quantified by 
measures of hyperemic resistance). Because of potential 
alterations in microvascular reactivity, cFFR might per-
form differently in diabetic patients. Thus the aim of this 
study was to explore whether diabetes might impact the 
diagnostic ability of cFFR compared with Pd/Pa or iFR 
versus adenosine-derived FFR ≤ 0.80.
Methods
Study population
We explored the impact of diabetes in a post-hoc analy-
sis of the CONTRAST study (clinicaltrials.gov identi-
fier NCT02184117). The design and results of this study 
have been previously published [8]. Briefly summarized, 
CONTRAST was an investigator-initiated, prospective 
diagnostic accuracy study that enrolled a multicenter, 
international cohort of patients undergoing routine 
FFR assessment for standard indications. Patients were 
recruited from 12 centers between June 2014 and April 
2015. Subsequent care proceeded as per routine from 
the clinical FFR measurement without further study-
related follow-up. Each subject gave informed consent 
as approved by the local institutional review board of 
that participating center. Subjects were excluded in case 
of prior coronary bypass surgery, known severe cardio-
myopathy (LV ejection fraction <30%) or LV hypertro-
phy (septal wall thickness >13 mm), contraindication to 
adenosine, or renal insufficiency such that an additional 
12–20 ml of contrast would, in the opinion of the opera-
tor, pose an unwarranted risk. In cases of multivessel dis-
ease, only the first lesion studied using FFR was included. 
Culprit lesions for an acute infarction were excluded, 
but non-culprit lesions were permitted. Standard demo-
graphic, clinical, and catheterization parameters were 
collected for each subject.
Measurements and core lab analysis
The physiology protocol and core lab analysis used for 
the study has been previously described [8]. Briefly, an 
initial period of at least 1  min provided a stable assess-
ment of resting physiology without further contrast 
injection. Next, a manual or injector-based IC bolus of 
contrast medium was given as per local practice for diag-
nostic angiography. The volume and type of IC contrast 
medium were not mandated but varied among sites and 
even among subjects at a single site but with a strong rec-
ommendation for 6–10 ml. A second IC bolus of contrast 
medium was injected using the same technique when 
conditions had returned to baseline (after approximately 
1  min). Next, after the return of baseline conditions, a 
manual IC bolus of adenosine was administered (dose at 
operators’ discretion but with a strong recommendation 
for 100–200 μg). A second, identical bolus of IC adeno-
sine was given after 1 min.
A subsequent period of at least 1 min provided a sec-
ond assessment of resting physiology before starting an 
adenosine infusion at a standard rate of 140  μg/kg/min 
via either a central or wide bore peripheral IV. The dura-
tion of the infusion was approximately 2 min, but could 
be prolonged or abbreviated as necessary. After stopping 
IV adenosine and waiting approximately 2 min for condi-
tions to return to baseline, a second, identical IV adeno-
sine infusion was performed. At the end of the procedure, 
an optional but recommended drift check was performed 
by bringing the pressure sensor back to the guide cath-
eter at the same location as equalization.
All pressure tracings were sent to the Cardiovas-
cular Research Foundation physiology core lab for 
standardized and centralized review. The core lab car-
ried out its post-hoc analysis without knowledge of the 
locally determined Pd/Pa value, IC substance (contrast 
medium or adenosine), enrolling site, or subject/lesion 
characteristics.
Statistical analysis and endpoints
The primary endpoint was accuracy against FFR ≤  0.80 
and compared using a McNemar test between met-
rics. Secondary endpoints included the area under the 
receiver operating characteristic (ROC) curve (compared 
using the DeLong method), sensitivity, and specificity. 
All the analyses were performed in diabetic and non-dia-
betic patients. Based on previous evidence [8], the binary 
thresholds were as follows: FFR ≤ 0.80; cFFR ≤ 0.83; Pd/
Pa < 0.92 and iFR < 0.90.
Continuous variables are presented as mean ±  stand-
ard deviation and were compared with independent sam-
ples Student t test. Categorical variables are expressed 
as count and percentages and were compared with 
Chi square or Fisher exact tests as appropriate. A Cox 
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proportional model was used for univariate and multi-
variate analysis to explore the role of diabetes in predict-
ing the cFFR disagreement with FFR. Applicable tests 
were two-tailed, and p < 0.05 was considered statistically 
significant. Analyses were performed in SPSS, version 
23.0 (SPSS Inc., Chicago, IL, USA) and MedCalc version 
12.5 (MedCalc Software, Ostend, Belgium).
Results
Of 763 subjects, 219 (29%) were diabetic. Compared with 
non-diabetic patients, those with diabetes were more fre-
quently women, had a higher body mass index, and more 
frequently had hypertension or dyslipidemia (Table  1). 
The 2 groups were well-balanced for clinical presentation 
(stable or unstable), coronary vessel studied, volume and 
type of intracoronary contrast, and volume of intracoro-
nary adenosine (Table 1).
As reported previously, a binary threshold of 
cFFR  ≤  0.83 produced an accuracy of 85.8%, supe-
rior to both Pd/Pa 78.5% and iFR 79.9% (McNemar 
p  <  0.001 versus both resting metrics), when compared 
with FFR ≤ 0.8 [8]. In this substudy, there was no signifi-
cant interaction between diabetes and accuracy; indeed, 
accuracy in subgroups of patients with or without dia-
betes was similar for cFFR (86.7 vs 85.4% respectively; 
p = 0.76), iFR (84.2 vs 80.0% respectively; p = 0.29) and 
Pd/Pa (81.3 vs 78.9% respectively; p  =  0.55) (Fig.  1). 
Overall, sensitivity was similar among the 3 metrics when 
comparing non-diabetics and diabetics, respectively 
(cFFR 78.6 vs 74.7%, p = 0.61; iFR 88.8 vs 77.2%, p = 0.05; 
Pd/Pa 78.8 vs 74.6%, p = 0.57), but cFFR improved speci-
ficity compared with iFR or Pd/Pa and there was no sig-
nificant interaction with diabetes status (cFFR 95.6 vs 
95.3%, p = 0.85; iFR 78.9 vs 78.6%, p = 0.89; Pd/Pa 84.0 vs 
82.9%, p = 0.96) (Fig. 1).
The area under the ROC curve was largest for cFFR 
compared with Pd/Pa and iFR which were equivalent 
in both diabetic (0.961 cFFR, 0.916 Pd/Pa, 0.911 iFR; 
DeLong p = 0.003 for cFFR vs iFR, p < 0.0001 for cFFR 
vs Pd/Pa and p = 0.66 for iFR vs Pd/Pa; Fig. 2) and non-
diabetic patients (0.928 cFFR, 0.870 Pd/Pa, 0.861 iFR; 
DeLong p < 0.0001 for cFFR vs iFR, p < 0.0001 for cFFR 
vs Pd/Pa and p  =  0.13 for iFR vs Pd/Pa; Fig.  2). There 
were no significant differences when ROC curves in dia-
betic and non-diabetic patients were compared (cFFR 
0.961 vs 0.928, DeLong p =  0.08; Pd/Pa 0.916 vs 0.870, 
DeLong p = 0.09; iFR 0.911 vs 0.861, DeLong p = 0.08).
As a physiologic explanation for the superior diagnos-
tic performance of cFFR compared to resting physiol-
ogy (either Pd/Pa or iFR), Fig.  3 shows that the modest 
hyperemia induced by cFFR determines a more linear 
and less scattered relationship versus FFR compared to 
that of resting physiology, irrespective of diabetes status. 
Indeed, compared with Pd/Pa and iFR, the correlation of 
cFFR with FFR was superior in both diabetic (r =  0.92 
and ICC =  0.85 for cFFR; r =  0.84 and ICC =  0.64 for 
iFR; r = 0.87 and ICC = 0.37 for Pd/Pa) or non-diabetic 
patients (r = 0.93 and ICC = 0.84 for cFFR; r = 0.80 and 
ICC = 0.56 for iFR; r = 0.85 and ICC = 0.38 for Pd/Pa; 
Fig. 3).
Diabetes did not predict agreement/disagreement 
between cFFR and FFR (p = 0.66) in a univariate analy-
sis. Also when diabetes was forced into a multivariable 
model, it did not significantly influence the accuracy of 
cFFR (adjusted p = 0.71) (Table 2).
Discussion
This sub-analysis of the CONTRAST study shows that 
there is no significant interaction between diabetes and 
the diagnostic performance of cFFR, therefore, the find-
ings of the main analysis can be extended to patients with 
diabetes. Contrast FFR provides superior diagnostic per-
formance compared with resting metrics (iFR and Pd/Pa) 
irrespective of diabetic status.
The CONTRAST study is the largest study to investi-
gate the diagnostic performance of cFFR and the present 
sub-analysis is the first to explore the impact of diabetes 
on cFFR performance compared with resting methods 
[23–25].
Diabetes mellitus is a well-known risk factor for cardio-
vascular disease [9–11]. The presence of diabetes accel-
erates the natural course of atherosclerosis, involving 
both proximal epicardial and distal small vessel coronary 
arteries with greater plaque ulceration and thrombosis 
and microvascular disease. Patients with diabetes have a 
variety of structural and functional microvascular coro-
nary abnormalities [12–18] that may translate into a 
reduction of hyperemic blood flow due to an impairment 
of microcirculatory vasodilation.
Some studies investigated the accuracy of FFR in dia-
betic patients. Yanagisawa et  al. compared FFR perfor-
mance in 96 and 149 patients with or without diabetes 
respectively and observed that there was no significant 
difference, although within diabetic patients, those with 
a poor glycemic control (glycated hemoglobin >7%) had 
a lower FFR specificity [19]. Domínguez-Franco et  al. 
found that deferring PCI in diabetic patients (29% of all 
patients) with a moderately severe coronary artery steno-
sis based on the FFR value was as safe as in patients with-
out diabetes [20]. Sahinarslan et al. analyzed 122 patients 
(29.5% with diabetes) with intermediate coronary lesions 
and observed that there was no difference between the 
FFR values in patients with or without diabetes who had 
been paired according to reference vessel diameter and 
degree of luminal narrowing of coronary lesions [21]. 
Reith et  al. evaluated FFR in 266 intermediate grade 
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Table 1 Baseline characteristics in patients with or without diabetes
ACS acute coronary syndrome, BMI body mass index, CAD coronary artery disease, GFR glomerular filtration rate, IC intracoronary, LAD left anterior descending 
coronary artery, LCx left circumflex coronary artery, MI myocardial infarction, NSTEMI non ST-segment elevation MI, PCI percutaneous coronary intervention, RCA right 
coronary artery, STEMI ST-segment elevation MI
* Only 549 of 763 patients received IC adenosine, while all other rows are based on 763 total
No diabetes (N = 544) Diabetes (N = 219) p value
Age (years) 65.4 ± 9.7 66.4 ± 9.7 0.24
Male 74.8% (407) 63.9% (140) 0.003
BMI (kg/m2) 26.8 ± 4.5 28.6 ± 5.0 <0.0001
Smoking (current or past) 47.8% (260) 47.0% (103) 0.85
Hypertension 67.5% (367) 81.3% (178) <0.0001
Dyslipidemia 61.4% (334) 79.5% (174) <0.0001
Family history of CAD 26.1% (142) 22.4% (49) 0.28
Renal dysfunction (eGFR < 60 ml/min) 8.6% (47) 12.3% (27) 0.12
Prior MI 24.1% (131) 30.6% (67) 0.06
Prior PCI 14.0% (76) 17.4% (38) 0.24
Peripheral vascular disease 3.7% (20) 6.4% (14) 0.10
Clinical presentation 0.37
 Stable 79.2% (431) 76.3% (167)
 ACS 20.8% (113) 23.7% (52)
 Unstable Angina 9.2% (50) 15.5% (34)
 NSTEMI 10.7% (58) 6.8% (15)
 STEMI 0.9% (5) 1.4% (3)
Coronary vessel 0.86
 Left main 3.1% (17) 3.7% (8)
 LAD 60.7% (330) 59.4% (130)
 LCx 17.5% (95) 19.6% (43)
 RCA 18.8% (102) 17.4% (38)
Contrast medium 0.03
 Iobitridol 5.3% (29) 5.0% (11)
 Iodixanol 24.3% (132) 26.0% (57)
 Iohexol 15.8% (86) 9.1% (20)
 Iomeprol 31.1% (169) 26.5% (58)
 Iopamidol 1.3% (7) 0.5% (1)
 Iopromide 7.9% (43) 11.9% (26)
 Ioversol 8.5% (46) 10.0% (22)
 Ioxaglate 5.9% (32) 11.0% (24)
Volume of IC contrast (ml) 7.9 ± 1.5 7.7 ± 1.6 0.03
 5 2.0% (11) 2.7% (6)
 6–7 39.7% (216) 49.3% (108)
 8–9 30.1% (164) 21.0% (46)
 10 27.9% (152) 26.9% (59)
 12 0.2% (1) 0% (0)
Dose of IC adenosine* (μg) 166.3 ± 46.1 171.2 ± 47.1 0.27
 <80 2.3% (9) 1.3% (2)
 80–90 7.1% (28) 7.1% (11)
 100–150 28.4% (112) 29.0% (45)
 160–200 48.5% (191) 45.2% (70)
 >200 13.7% (54) 17.4% (27)
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lesions of 224 patients (113 non-diabetics and 111 diabet-
ics) with stable CAD, also exploring the role of adequate 
glycemic control (defined as glycated hemoglobin <7%). 
They found that FFR accuracy was not affected by dia-
betic status and its glycemic control [22]. In the FAME-2 
trial, the FFR guided PCI was superior to medical therapy 
for the primary end point (composite of death from any 
cause, nonfatal myocardial infarction, or urgent revas-
cularization within 2  years) in patients with or without 
diabetes (28 and 72% respectively) with an absence of sig-
nificant interaction between the two sub-groups interac-
tion p = 0.50) [4].
Interestingly, some data have questioned the accuracy 
of FFR is some cases. Although FFR and coronary flow 
velocity reserve (CFVR) have an equivalent diagnostic 
accuracy for inducible myocardial ischemia, it has been 
shown that they provide discordant results in 30–40% of 
cases, which was suggested to have a significant impact 
on clinical outcomes, particularly when FFR is normal 
and CFVR abnormal that generally indicates predomi-
nant microvascular involvement in coronary artery dis-
ease [26, 27]. Therefore it cannot be excluded that the 
accuracy of FFR, and thus also of cFFR, may be affected 
in case of microvascular disease as occurs in patients 
with diabetes. Indeed, a recent study has showed that in 
patients with diabetes, particularly those with previous 
MI, FFR-based deferred revascularization was associ-
ated with poor medium-term outcomes suggesting that 
Fig. 1 Diagnostic performance of cFFR, iFR and Pd/Pa in patients with or without diabetes. Accuracy, specificity, and sensitivity of each metric are 
reported for patients with (red bars) and without (blue bars) diabetes, demonstrating absence of heterogeneity in these subgroups
Fig. 2 Diagnostic performance expressed by the area under the ROC curve for each metric in patients with or without diabetes. In patients with or 
without diabetes, contrast FFR (red line) has the largest area under the ROC curve, while iFR (blue line) and Pd/Pa (black line) have equivalent areas
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the combining of FFR with imaging techniques may be 
useful to guide our treatment strategy in these patients 
with high-risk, fast-progressing disease [28]. Comparing 
FFR-guided deferred revascularization in patients with 
and without diabetes, Kennedy et  al. also showed that 
those with diabetes were associated with a significantly 
higher rate of target lesion failure [29]. Accordingly, a 
recent study by Liu et al. showed that a higher FFR was 
associated with lower rates of death, myocardial infarc-
tion and revascularization among non-diabetic patients 
with deferred PCI, but in diabetic patients with deferred 
revascularization, FFR was not able to differentiate the 
risk of cardiovascular events [30].
Whether intravascular imaging, may impact on this 
higher failure rate remains unexplored, but the COM-
BINE study, the first prospective multicenter combining 
FFR and optical coherence tomography, will contribute 
to clarify this issue investigating the hypothesis that add-
ing the study of plaque morphology to FFR in interme-
diate lesions may better predict events in patients with 
diabetes [31].
Although few data exist on the clinical value of FFR in 
diabetic patients, the impact of diabetes and any poten-
tially associated microvascular dysfunction was previ-
ously unknown for cFFR performance. Indeed, whether 
the submaximal vasodilatation induced by contrast 
medium compared with adenosine might affect the accu-
racy of cFFR measurement in patients with diabetes had 
Fig. 3 Scatterplots of each metric with FFR in patients with or with-
out diabetes. Resting physiology (either Pd/Pa or iFR) displays a less 
linear and more scattered relationship with FFR than does modest 
hyperemia (contrast FFR) in both diabetic (red dots) and non-diabetic 
patients (blue dots), as shown visually by the raw data and its local 
regression (thick blue line with dashed 95% confidence intervals) 
and quantified by correlation coefficients (r from Pearson, ICC from 
intraclass correlation)
Table 2 Predictors of cFFR disagreement with FFR
ACS acute coronary syndrome, BMI body mass index, CAD coronary artery 
disease, GFR glomerular filtration rate, IC intracoronary, MI myocardial infarction, 
PCI percutaneous coronary intervention
* Only 549 of 763 patients received IC adenosine, while all other rows are based 
on 763 total
Univariate Multivariate
p value p value
Age (years) 0.06 0.34
Male 0.54
BMI (kg/m2) 0.11 0.59
Diabetes 0.66 0.71
Smoking (current or past) 0.59
Hypertension 0.50
Dyslipidemia 0.36
Family history of CAD 0.87
Renal dysfunction (eGFR <60 ml/min) 0.09 0.30
Prior MI 0.58
Prior PCI 0.89
Peripheral vascular disease 0.42
Clinical presentation (stable or ACS) 0.89
Coronary vessel 0.045 0.89
Syntax segment 0.004 0.26
Contrast medium 0.004 0.44
Volume of IC contrast 0.005 0.37
Dose of IC adenosine* 0.038 0.76
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never been explored before. Our novel results found no 
significant heterogeneity between subgroups stratified by 
diabetes, and that the overall results of the CONTRAST 
study can be extended to all patients irrespective of dia-
betic status. Therefore, cFFR has been proven accurate 
and superior to resting metrics in patients with diabetes 
as well as in those without diabetes.
Limitations
This is an unplanned post-hoc analysis of the CON-
TRAST study, which was not designed or powered to 
investigate the diabetic subgroup specifically. Therefore, 
our exploratory analysis should be considered hypothe-
sis-generating and needs to be confirmed in further tri-
als. Additionally, our sub-analysis shares the limitations 
of the main study [8], namely the short-acting nature of 
contrast-induced hyperemia and lack of clinical data 
regarding contrast-induced nephropathy. Finally, being 
cFFR measured during submaximal hyperemia, it shares 
the same FFR limitations related to hyperemia in the set-
ting of microvascular dysfunction.
Clinical relevance and conclusions
When performing physiological lesion assessment, 
some operators prefer to avoid adenosine due to rare 
side effects and minimal but nonzero added time and 
expense. Moreover, adenosine is still expensive or una-
vailable in some areas of the world, and sporadic patients 
have contraindications.
Contrast FFR provides superior diagnostic perfor-
mance than Pd/Pa or iFR for predicting FFR irrespec-
tive of diabetes. Although FFR remains the reference 
standard for diagnostic certainty, for clinical scenarios or 
healthcare systems in which adenosine is contraindicated 
or prohibitively expensive, cFFR may represent a simple 
alternative technique to adenosine-FFR for invasive coro-
nary physiological assessment in diabetic as well as non-
diabetic patients.
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